AngioSoma, Inc. is a publicly traded (OTCQB:SOAN) clinical stage biopharmaceutical company focused on improving the effectiveness of current standard-of-care treatments, especially related to endovascular interventions in the treatment of peripheral artery disease (‘PAD’). Our lead pharmaceutical product Liprostin™, a treatment for PAD, has successfully completed FDA Phase I and three Phase II clinical trials, and we are in discussions with several contract research organizations for rapid completion of our U.S. Food and Drug Administration (‘FDA’) approved protocol for Phase III with submission of our new drug application for marketing in the U.S. and its territories.